AI drives down healthcare costs, leaving chronic-care management as the investment case
AI is driving diagnosis, analysis and asynchronous care costs toward zero, but complex chronic-care management may retain value because physicians must coordinate treatment over years.

Artificial intelligence is pushing the cost of diagnosis, analysis and asynchronous care toward zero, while complex longitudinal management of chronic diseases may remain a promising healthcare investment because it still requires physicians.
In a Nov. 20 interview on Anthony Pompliano’s X account, Saad Hone, founder of Hone Health, divided healthcare into diagnosis, analysis and care. He said AI would sharply reduce costs in the first two areas and in asynchronous virtual care, while doctors would remain essential to managing patients over several years.
Hone said full-body MRI scans had fallen from $10,000 to $2,500 and then to about $500, while Function’s 100-biomarker testing dropped from $1,200 three years ago to $60. He described diagnosis as becoming a high-volume, low-margin business with little room for a durable cost advantage.
In analysis, services including ChatGPT or OpenAI, Perplexity and Claude can interpret test data that once served as a core advantage for healthcare companies. Asynchronous care is also moving toward lower costs as online forms and AI-assisted prescription refills replace more physician involvement.
Complex longitudinal care requires physicians to assess multiple chronic conditions, build personalized protocols and coordinate treatment over three to six years. Hone Health offers a 70-marker blood test and a consultation with a physician for $65, while AI supports care across multiple therapeutic categories. Hone said longevity care using 300 to 500 biomarkers could move from a service costing $30,000 to $40,000 a year for affluent clients to a model priced closer to primary care.